FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
BiologicsStephen J. Fallon, Ph.D.
FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.
High risk -
DrugsArmstrong County Memorial Hospital
FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.
Medium -
BiologicsNamita A. Goyal, M.D.
FDA warned clinical investigator Dr. Namita Goyal over a biologic trial that enrolled ineligible subjects and kept poor records.
High risk -
DrugsLouisiana State University Health Science Center IRB
FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.
Medium -
DrugsNew York State Psychiatric Institute IRB
FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.
High risk -
DevicesNobles Medical Technology II, Inc.
FDA warns Nobles Medical Technology II over oversight failures in NobleStitch EL clinical study.
High risk -
DrugsJeffrey W. Taub, M.D./Children's Hospital of Michigan
FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.
High risk -
DrugsLuis Javier Pena-Hernandez, M.D., FCCP
FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.
High risk -
DrugsSabine S. Hazan, M.D.
FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.
High risk